Dr. Christopher Missling
Equibles does not estimate personal net worth.
About Dr. Christopher Missling
Earlier roles on record: CEO at Anavex Life Sciences Corp. (AVXL) until April 30, 2026. The proxy statement of Anavex Life Sciences Corp. reports total compensation of $2,783,700 for Dr. Christopher Missling in fiscal 2024, including a base salary of $700,000. Disclosed compensation is on record for 7 fiscal years. Dr. Christopher Missling has spoken on 6 earnings calls across 1 company, most recently for Anavex Life Sciences Corp. on February 9, 2026. The companies whose calls Dr. Christopher Missling spoke on are classified in the Healthcare sector.
Dr. Christopher Missling on recent calls
“Thank you for being with us today to review our first quarter financial results and quarterly business update. As we enter 2026, we continue to progress our innovative clinical pipeline with particular focus on our lead candidate, oral blakarmazine, in early Alzheimer's disease.”
“We appreciate everyone joining us on today's conference call to review our most recently reported financial results and to provide a business update. We are excited with the continued advancement of our lead product candidate ANAVEX 2-73 in Alzheimer's disease and Rett syndrome.”
“We appreciate everyone joining us on today’s conference call to review our most recently reported financial results and to provide a business update. We are pleased with the continued advancement regarding our lead product candidate, ANAVEX 2-73 in Alzheimer’s disease and Rett syndrome.”
“We really appreciate everyone joining us on today's conference call to review our most recent reported financial results and to provide a corporate business update.”
“We appreciate everyone joining us for today's conference call to review our financial results and clinical updates. First, I would like to provide new key clinical updates given the very encouraging data of the U.S. Rett syndrome study.”
Affiliation history
-
Start not stated–2026-04-30
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Anavex Life Sciences Corp. (AVXL) | President, Chief Executive Officer and Director | $700,000 | $2,783,700 |
| 2023 | Anavex Life Sciences Corp. (AVXL) | President, Chief Executive Officer and Director | $700,000 | $3,894,453 |
| 2022 | Anavex Life Sciences Corp. (AVXL) | President, Chief Executive Officer and Director | $586,400 | $6,753,643 |
| 2021 | Anavex Life Sciences Corp. (AVXL) | President, Chief Executive Officer, and Director | $550,000 | $9,417,057 |
| 2020 | Anavex Life Sciences Corp. (AVXL) | President, Chief Executive Officer, and Director | $550,000 | $1,841,048 |
| 2019 | Anavex Life Sciences Corp. (AVXL) | President, Chief Executive Officer, and Director | $512,500 | $3,380,039 |
| 2018 | Anavex Life Sciences Corp. (AVXL) | President, Chief Executive Officer, and Director | $500,000 | $2,549,889 |